API
< Back to all clusters
[POLITICS] · India · 14 sources

started · updated

Supreme Court slams massive markups on cancer drugs

The Supreme Court of India has expressed severe concern over the massive price disparities in the pharmaceutical sector, specifically regarding life-saving cancer medications. A bench comprising Justices Vikram Nath and Sandeep Mehta described the ten-fold markup on certain drugs as ‘carnage,’ noting instances where a medicine supplied to retailers for approximately Rs 2,700 carried a Maximum Retail Price (MRP) of Rs 27,000.

The Court questioned the existing regulatory framework under the Drugs (Prices Control) Order (DPCO), 2013, specifically the distinction between essential and non-essential medicines. The justices proposed the possibility of implementing a uniform 16 percent margin cap across all pharmaceutical products to ensure transparency and protect consumers.

Additionally, the bench flagged the practices of corporate hospitals that mandate patients to purchase medicines from in-house pharmacies, often implying that treatment may not be guaranteed if medicines are sourced externally. The Court noted that such practices place an undue financial burden on patients and taxpayers, particularly those covered under government health schemes. Solicitor General Tushar Mehta stated that the Union government is looking for a way to balance the interests of manufacturers, retailers, and patients.

Entities

Ashwini Upadhyay · Government of India · National Pharmaceutical Pricing Authority · Sandeep Mehta · Supreme Court of India · Surya Kant · Tushar Mehta · Vikram Nath

Claims

What the coverage asserts, and how many sources carry each claim.

Sources